<DOC>
	<DOCNO>NCT01001624</DOCNO>
	<brief_summary>The purpose study assess efficacy Melanil facial cream treatment melasma . The duration double-blind phase 3 clinical trial 54 week . The control group receive treatment Hydroquinone ( 2 % ) . The estimated number subject recruit randomize study 150 . The primary outcome measure : Melasma Area Severity Index ( MASI ) score assess begin study week 4 , 8 , 12 54 . Photographs take begin study week 8 , 12 54 evaluate two independent dermatologist . Occurrence adverse effect also assess .</brief_summary>
	<brief_title>Melanil Treatment Melasma</brief_title>
	<detailed_description />
	<mesh_term>Melanosis</mesh_term>
	<mesh_term>Hydroquinone</mesh_term>
	<criteria>Clinical diagnosis Melasma Fitzpatrick 's skin type I IV Signed informed consent Given verbal agreement protection UV light treatment usage physical barrier ( umbrellas , cap , hat , etc ) . Fitzpatrick 's skin type V VI Treatment steroid within duration clinical trial . Oral contraception within duration clinical trial Usage cosmetic within duration clinical trial Treatment Clofazimine within duration clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Cosmetic</keyword>
	<keyword>Facial cream</keyword>
	<keyword>Melasma</keyword>
	<keyword>Melanil</keyword>
</DOC>